CMS finalizes rule to promote value-based drug
purchasing
The CMS released a final rule meant to promote value-based
purchasing of prescription drugs by making it easier for health insurers,
states and drugmakers to enter into such arrangements. The final rule updates
Medicaid's drug rebate program law and revises the average manufacturer price
and best price reporting requirements, with the changes taking effect in
January 2022.
Full Story: Becker's
Hospital Review (12/21)
No comments:
Post a Comment